FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1934853083> ?p ?o ?g. }

• W1934853083 endingPage "560" @default.
• W1934853083 startingPage "553" @default.
• W1934853083 abstract "While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer." @default.
• W1934853083 created "2016-06-24" @default.
• W1934853083 creator A5005027857 @default.
• W1934853083 creator A5005933314 @default.
• W1934853083 creator A5011928803 @default.
• W1934853083 creator A5015598872 @default.
• W1934853083 creator A5015641919 @default.
• W1934853083 creator A5019406140 @default.
• W1934853083 creator A5024676627 @default.
• W1934853083 creator A5026351538 @default.
• W1934853083 creator A5026357453 @default.
• W1934853083 creator A5032561728 @default.
• W1934853083 creator A5043984377 @default.
• W1934853083 creator A5045587524 @default.
• W1934853083 creator A5047808702 @default.
• W1934853083 creator A5049386904 @default.
• W1934853083 creator A5049872669 @default.
• W1934853083 creator A5057146015 @default.
• W1934853083 creator A5060913021 @default.
• W1934853083 creator A5063818496 @default.
• W1934853083 creator A5065244228 @default.
• W1934853083 creator A5066094957 @default.
• W1934853083 creator A5070060016 @default.
• W1934853083 creator A5075932421 @default.
• W1934853083 creator A5083074248 @default.
• W1934853083 date "2016-04-15" @default.
• W1934853083 modified "2023-09-25" @default.
• W1934853083 title "A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology" @default.
• W1934853083 cites W1757407923 @default.
• W1934853083 cites W1943541966 @default.
• W1934853083 cites W2008322008 @default.
• W1934853083 cites W2024177665 @default.
• W1934853083 cites W2029678186 @default.
• W1934853083 cites W2076925883 @default.
• W1934853083 cites W2087202011 @default.
• W1934853083 cites W2100439220 @default.
• W1934853083 cites W2106240758 @default.
• W1934853083 cites W2106787323 @default.
• W1934853083 cites W2108661938 @default.
• W1934853083 cites W2115551774 @default.
• W1934853083 cites W2122866527 @default.
• W1934853083 cites W2125201819 @default.
• W1934853083 cites W2134392974 @default.
• W1934853083 cites W2137991416 @default.
• W1934853083 cites W2144182296 @default.
• W1934853083 cites W2152256906 @default.
• W1934853083 cites W2152362765 @default.
• W1934853083 cites W2155167083 @default.
• W1934853083 cites W2171075804 @default.
• W1934853083 cites W2171136968 @default.
• W1934853083 cites W2185378752 @default.
• W1934853083 cites W2338576041 @default.
• W1934853083 doi "https://doi.org/10.4143/crt.2015.155" @default.
• W1934853083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4843742" @default.
• W1934853083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26323641" @default.
• W1934853083 hasPublicationYear "2016" @default.
• W1934853083 type Work @default.
• W1934853083 sameAs 1934853083 @default.
• W1934853083 citedByCount "17" @default.
• W1934853083 countsByYear W19348530832016 @default.
• W1934853083 countsByYear W19348530832017 @default.
• W1934853083 countsByYear W19348530832018 @default.
• W1934853083 countsByYear W19348530832019 @default.
• W1934853083 countsByYear W19348530832020 @default.
• W1934853083 countsByYear W19348530832021 @default.
• W1934853083 countsByYear W19348530832022 @default.
• W1934853083 countsByYear W19348530832023 @default.
• W1934853083 crossrefType "journal-article" @default.
• W1934853083 hasAuthorship W1934853083A5005027857 @default.
• W1934853083 hasAuthorship W1934853083A5005933314 @default.
• W1934853083 hasAuthorship W1934853083A5011928803 @default.
• W1934853083 hasAuthorship W1934853083A5015598872 @default.
• W1934853083 hasAuthorship W1934853083A5015641919 @default.
• W1934853083 hasAuthorship W1934853083A5019406140 @default.
• W1934853083 hasAuthorship W1934853083A5024676627 @default.
• W1934853083 hasAuthorship W1934853083A5026351538 @default.
• W1934853083 hasAuthorship W1934853083A5026357453 @default.
• W1934853083 hasAuthorship W1934853083A5032561728 @default.
• W1934853083 hasAuthorship W1934853083A5043984377 @default.
• W1934853083 hasAuthorship W1934853083A5045587524 @default.
• W1934853083 hasAuthorship W1934853083A5047808702 @default.
• W1934853083 hasAuthorship W1934853083A5049386904 @default.
• W1934853083 hasAuthorship W1934853083A5049872669 @default.
• W1934853083 hasAuthorship W1934853083A5057146015 @default.
• W1934853083 hasAuthorship W1934853083A5060913021 @default.
• W1934853083 hasAuthorship W1934853083A5063818496 @default.
• W1934853083 hasAuthorship W1934853083A5065244228 @default.
• W1934853083 hasAuthorship W1934853083A5066094957 @default.
• W1934853083 hasAuthorship W1934853083A5070060016 @default.
• W1934853083 hasAuthorship W1934853083A5075932421 @default.
• W1934853083 hasAuthorship W1934853083A5083074248 @default.
• W1934853083 hasBestOaLocation W19348530831 @default.
• W1934853083 hasConcept C121608353 @default.
• W1934853083 hasConcept C126322002 @default.
• W1934853083 hasConcept C143998085 @default.
• W1934853083 hasConcept C189528381 @default.
• W1934853083 hasConcept C2776694085 @default.
• W1934853083 hasConcept C2779786085 @default.

• next